...
search icon
acet-img

Adicet Bio Inc, Common Stock

ACET

NMQ

$0.9734

-$0.03

(-3%)

1D
Industry: Health Care Providers & Services Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$80.21M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
302.81K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.64
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.81 L
$2.61 H
$0.9734

About Adicet Bio Inc, Common Stock

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts. more

Industry: Health Care Providers & ServicesSector: Health Care

Returns

Time FrameACETSectorS&P500
1-Week Return-1.87%1.67%0.11%
1-Month Return3.67%3.31%1.23%
3-Month Return6.5%2.21%2.87%
6-Month Return-38%-4.82%8.93%
1-Year Return-63.81%1.22%22.83%
3-Year Return-92.32%15.75%42.13%
5-Year Return-90.85%42.34%83.14%
10-Year Return-99.18%103.03%189.73%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue995.00K17.90M9.73M24.99M-[{"date":"2019-12-31","value":3.98,"profit":true},{"date":"2020-12-31","value":71.64,"profit":true},{"date":"2021-12-31","value":38.94,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue125.00K--5.01M6.10M[{"date":"2019-12-31","value":2.05,"profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":82.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit870.00K17.90M9.73M19.98M(6.10M)[{"date":"2019-12-31","value":4.35,"profit":true},{"date":"2020-12-31","value":89.6,"profit":true},{"date":"2021-12-31","value":48.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-30.52,"profit":false}]
Gross Margin87.44%100.00%100.00%79.96%(Infinity%)[{"date":"2019-12-31","value":87.44,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":79.96,"profit":true},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses32.38M57.09M71.16M97.54M152.04M[{"date":"2019-12-31","value":21.3,"profit":true},{"date":"2020-12-31","value":37.55,"profit":true},{"date":"2021-12-31","value":46.81,"profit":true},{"date":"2022-12-31","value":64.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(31.39M)(39.19M)(61.43M)(72.55M)(152.04M)[{"date":"2019-12-31","value":-3138800000,"profit":false},{"date":"2020-12-31","value":-3919100000,"profit":false},{"date":"2021-12-31","value":-6143300000,"profit":false},{"date":"2022-12-31","value":-7255100000,"profit":false},{"date":"2023-12-31","value":-15203800000,"profit":false}]
Total Non-Operating Income/Expense-349.00K(776.00K)6.44M19.33M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":1.81,"profit":true},{"date":"2021-12-31","value":-4.01,"profit":false},{"date":"2022-12-31","value":33.32,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(28.12M)(39.49M)(62.12M)(69.79M)(142.66M)[{"date":"2019-12-31","value":-2811900000,"profit":false},{"date":"2020-12-31","value":-3949300000,"profit":false},{"date":"2021-12-31","value":-6212400000,"profit":false},{"date":"2022-12-31","value":-6979000000,"profit":false},{"date":"2023-12-31","value":-14265800000,"profit":false}]
Income Taxes19.00K(2.81M)(125.00K)(2.76M)5.93M[{"date":"2019-12-31","value":0.32,"profit":true},{"date":"2020-12-31","value":-47.47,"profit":false},{"date":"2021-12-31","value":-2.11,"profit":false},{"date":"2022-12-31","value":-46.56,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes-(36.68M)(62.00M)(67.03M)(148.59M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3667800000,"profit":false},{"date":"2021-12-31","value":-6199900000,"profit":false},{"date":"2022-12-31","value":-6702900000,"profit":false},{"date":"2023-12-31","value":-14858810500,"profit":false}]
Income From Continuous Operations-(36.68M)(62.00M)(69.79M)(142.66M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-3667800000,"profit":false},{"date":"2021-12-31","value":-6199900000,"profit":false},{"date":"2022-12-31","value":-6979000000,"profit":false},{"date":"2023-12-31","value":-14265800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(28.14M)(36.68M)(62.00M)(67.03M)(142.66M)[{"date":"2019-12-31","value":-2813800000,"profit":false},{"date":"2020-12-31","value":-3667800000,"profit":false},{"date":"2021-12-31","value":-6199900000,"profit":false},{"date":"2022-12-31","value":-6702900000,"profit":false},{"date":"2023-12-31","value":-14265800000,"profit":false}]
EPS (Diluted)(16.52)(5.68)(2.07)(1.71)(3.32)[{"date":"2019-12-31","value":-1652,"profit":false},{"date":"2020-12-31","value":-568,"profit":false},{"date":"2021-12-31","value":-207,"profit":false},{"date":"2022-12-31","value":-171,"profit":false},{"date":"2023-12-31","value":-332,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ACET
Cash Ratio 10.42
Current Ratio 10.64

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ACET
ROA (LTM) -33.50%
ROE (LTM) -58.04%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ACET
Debt Ratio Lower is generally better. Negative is bad. 0.14
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.86

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ACET
Trailing PE NM
Forward PE NM
P/S (TTM) 9.72
P/B 0.39
Price/FCF NM
EV/R 2.14
EV/Ebitda NM
PEG 0.82

FAQs

What is Adicet Bio Inc share price today?

Adicet Bio Inc (ACET) share price today is $0.9734

Can Indians buy Adicet Bio Inc shares?

Yes, Indians can buy shares of Adicet Bio Inc (ACET) on Vested. To buy Adicet Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACET stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Adicet Bio Inc be purchased?

Yes, you can purchase fractional shares of Adicet Bio Inc (ACET) via the Vested app. You can start investing in Adicet Bio Inc (ACET) with a minimum investment of $1.

How to invest in Adicet Bio Inc shares from India?

You can invest in shares of Adicet Bio Inc (ACET) via Vested in three simple steps:

  • Click on Sign Up or Invest in ACET stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Adicet Bio Inc shares
What is Adicet Bio Inc 52-week high and low stock price?

The 52-week high price of Adicet Bio Inc (ACET) is $2.61. The 52-week low price of Adicet Bio Inc (ACET) is $0.81.

What is Adicet Bio Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Adicet Bio Inc (ACET) is 0.39

What is the Market Cap of Adicet Bio Inc?

The market capitalization of Adicet Bio Inc (ACET) is $80.21M

What is Adicet Bio Inc’s stock symbol?

The stock symbol (or ticker) of Adicet Bio Inc is ACET

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top